These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 21673090)

  • 21. Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
    Chen YJ; Yeh MH; Yu MC; Wei YL; Chen WS; Chen JY; Shih CY; Tu CY; Chen CH; Hsia TC; Chien PH; Liu SH; Yu YL; Huang WC
    Breast Cancer Res; 2013 Nov; 15(6):R108. PubMed ID: 24216290
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer.
    Zhang L; Ngo JA; Wetzel MD; Marchetti D
    Neoplasia; 2015 Jan; 17(1):101-13. PubMed ID: 25622903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib.
    Kancha RK; von Bubnoff N; Bartosch N; Peschel C; Engh RA; Duyster J
    PLoS One; 2011; 6(10):e26760. PubMed ID: 22046346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
    Li D; Marchenko ND
    Oncotarget; 2017 Jan; 8(4):5823-5833. PubMed ID: 27791982
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
    Chen FL; Xia W; Spector NL
    Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor.
    Aird KM; Ghanayem RB; Peplinski S; Lyerly HK; Devi GR
    Mol Cancer Ther; 2010 May; 9(5):1432-42. PubMed ID: 20406946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells.
    Komurov K; Tseng JT; Muller M; Seviour EG; Moss TJ; Yang L; Nagrath D; Ram PT
    Mol Syst Biol; 2012; 8():596. PubMed ID: 22864381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
    Juliachs M; Castillo-Ávila W; Vidal A; Piulats JM; Garcia Del Muro X; Condom E; Hernández-Losa J; Teixidó C; Pandiella A; Graupera M; Casanovas O; Germà JR; Villanueva A; Viñals F
    Int J Cancer; 2013 Jul; 133(1):235-46. PubMed ID: 23292912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HER Specific TKIs Exert Their Antineoplastic Effects on Breast Cancer Cell Lines through the Involvement of STAT5 and JNK.
    Gschwantler-Kaulich D; Grunt TW; Muhr D; Wagner R; Kölbl H; Singer CF
    PLoS One; 2016; 11(1):e0146311. PubMed ID: 26735495
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells.
    Jin Q; Yuan LX; Boulbes D; Baek JM; Wang YN; Gomez-Cabello D; Hawke DH; Yeung SC; Lee MH; Hortobagyi GN; Hung MC; Esteva FJ
    Breast Cancer Res; 2010; 12(6):R96. PubMed ID: 21080941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers.
    Raja SM; Clubb RJ; Ortega-Cava C; Williams SH; Bailey TA; Duan L; Zhao X; Reddi AL; Nyong AM; Natarajan A; Band V; Band H
    Cancer Biol Ther; 2011 Jan; 11(2):263-76. PubMed ID: 21088503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biological and biochemical effects of CP-654577, a selective erbB2 kinase inhibitor, on human breast cancer cells.
    Barbacci EG; Pustilnik LR; Rossi AM; Emerson E; Miller PE; Boscoe BP; Cox ED; Iwata KK; Jani JP; Provoncha K; Kath JC; Liu Z; Moyer JD
    Cancer Res; 2003 Aug; 63(15):4450-9. PubMed ID: 12907618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
    Watson SS; Dane M; Chin K; Tatarova Z; Liu M; Liby T; Thompson W; Smith R; Nederlof M; Bucher E; Kilburn D; Whitman M; Sudar D; Mills GB; Heiser LM; Jonas O; Gray JW; Korkola JE
    Cell Syst; 2018 Mar; 6(3):329-342.e6. PubMed ID: 29550255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA.
    Paroni G; Fratelli M; Gardini G; Bassano C; Flora M; Zanetti A; Guarnaccia V; Ubezio P; Centritto F; Terao M; Garattini E
    Oncogene; 2012 Jul; 31(29):3431-43. PubMed ID: 22056878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program.
    Gorlick R; Kolb EA; Houghton PJ; Morton CL; Phelps D; Schaiquevich P; Stewart C; Keir ST; Lock R; Carol H; Reynolds CP; Maris JM; Wu J; Smith MA
    Pediatr Blood Cancer; 2009 Oct; 53(4):594-8. PubMed ID: 19554571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of lysosome-targeting drugs with anti-inflammatory activity as potential invasion inhibitors of treatment resistant HER2 positive cancers.
    Hansen MB; Postol M; Tvingsholm S; Nielsen IØ; Dietrich TN; Puustinen P; Maeda K; Dinant C; Strauss R; Egan D; Jäättelä M; Kallunki T
    Cell Oncol (Dordr); 2021 Aug; 44(4):805-820. PubMed ID: 33939112
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice.
    Strecker TE; Shen Q; Zhang Y; Hill JL; Li Y; Wang C; Kim HT; Gilmer TM; Sexton KR; Hilsenbeck SG; Osborne CK; Brown PH
    J Natl Cancer Inst; 2009 Jan; 101(2):107-13. PubMed ID: 19141783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Src and CXCR4 are involved in the invasiveness of breast cancer cells with acquired resistance to lapatinib.
    De Luca A; D'Alessio A; Gallo M; Maiello MR; Bode AM; Normanno N
    Cell Cycle; 2014; 13(1):148-56. PubMed ID: 24200972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.